Palak Desai
Family · Newark, DENPI 1992291280
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,971 of the $5,701 with a category attached, or 69.7%. 21 manufacturers reported payments, led by Medtronic at 49.3% of the total. Reporting peaked in 2023 at $3,130 and has fallen 77.3% since, to $709 in 2025. Among family clinicians in DE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 207 payments — averaging $27.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$817
- Collegium Pharmaceutical, Inc.$687
- Scilex Pharmaceuticals Inc.$361
- AbbVie$248
- Valinor Pharma, LLC$126
- plus $652 from 15 others
What the payments were for
- Travel & lodging$1,67629%
- Food & beverage$3,97170%
- Education$541%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 24 | $2,809 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 61 | $817 |
| Collegium Pharmaceutical, Inc. | 53 | $687 |
| Scilex Pharmaceuticals Inc. | 18 | $361 |
| AbbVie | 10 | $248 |
| Valinor Pharma, LLC | 7 | $126 |
| Azurity Pharmaceuticals, Inc. | 2 | $93 |
| Vertex | 4 | $82 |
| GRT US Holding, Inc. | 4 | $72 |
| Kowa Pharmaceuticals America, Inc. | 5 | $70 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $59 |
| Biodelivery Sciences International, Inc. | 4 | $55 |
| IBSA Pharma Inc. | 2 | $41 |
| Redhill Biopharma Inc. | 2 | $36 |
| Pfizer | 2 | $31 |
| Biogen | 1 | $24 |
| Lilly USA, LLC | 1 | $23 |
| Arbor Pharmaceuticals, Inc. | 1 | $19 |
| Biohaven Pharmaceuticals, Inc. | 1 | $18 |
| Novo Nordisk | 1 | $16 |
| Almatica Pharma LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SYNCHROMEDII$1,935
- INTELLIS ADAPTIVESTIM$120
How this compares
$5,701 in reported general payments places this provider in the 90th percentile of 523 family providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RelistorMethylnaltrexone Bromide | 49 | $119,930 |
| BelbucaBuprenorphine Hcl | 71 | $69,783 |
| Xtampza ErOxycodone Myristate | 106 | $45,762 |
| Buprenorphine | 185 | $29,150 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 741 | $23,207 |
| OxycontinOxycodone Hcl | 36 | $19,050 |
| Lidocaine | 90 | $12,870 |
| MovantikNaloxegol Oxalate | 29 | $11,320 |
| Morphine Sulfate ErMorphine Sulfate | 393 | $11,224 |
| Oxycodone Hcl | 677 | $10,627 |
| Metaxalone | 27 | $10,529 |
| Fentanyl | 41 | $8,471 |
| Tramadol Hcl ErTramadol Hcl | 89 | $7,993 |
| Gabapentin | 401 | $7,625 |
| ButransBuprenorphine | 15 | $7,391 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $817 | $119,93049 claims |
| Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er | $687 | $115,545177 claims |
| Redhill Biopharma Inc.Movantik | $36 | $11,32029 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 523 family providers in Delaware.
Other family in Newark
- Kathy GallagherNewark$53K
- Jodie DelesioNewark$50K
- Melanie HiesterNewark$9K
- Samatha GrayNewark$9K
- Byron MayNewark$8K
- Clare MatisNewark$8K
- Christine MazzolaNewark$7K
- Kelsey FrybergerNewark$7K
- Colleen AllenNewark$7K
- Mallory KowalskiNewark$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.